About Vir Biotechnology Inc.

Vir Biotechnology Inc., founded in 2016, has rapidly advanced from a clinical-stage company to commercial operations by developing innovative immunotherapies for serious infectious diseases. The company has built a comprehensive platform combining antibody engineering, T-cell technologies, and immune modulation. VIR stock price reflects the company's commercial progress and continued innovation in infectious disease treatment.

Led by CEO George Scangos, former Biogen CEO, Vir has successfully advanced multiple programs through clinical development while building strategic partnerships with major pharmaceutical companies. The management team combines deep immunology expertise with proven commercial execution capabilities. Leadership's strategic focus on addressing serious infectious diseases has been instrumental in building a sustainable commercial platform and driving VIR stock price appreciation.

Vir operates by developing and commercializing immunotherapies for infectious diseases including chronic hepatitis B, influenza, and other viral infections using proprietary antibody platforms and immune system modulation approaches. The company generates revenue from commercial products and strategic partnerships. With established commercial products providing revenue foundation, multiple pipeline programs offering continued growth potential, and leadership in infectious disease immunotherapy, VIR offers investors exposure to innovative infectious disease therapeutics with both current revenues and significant pipeline value in addressing global health challenges.